The Pharmaco -, Population and Evolutionary Dynamics of Multi-drug Therapy: Experiments with S. aureus and E. coli and Computer Simulations

PLoS Pathogens

Volumn 9, Issue 4, 2013, Pages

  Ankomah, Peter ^a   Johnson, Paul J T ^a,b   Levin, Bruce R ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIUM CULTURE; COMPUTER SIMULATION; DRUG EFFICACY; ESCHERICHIA COLI; EVOLUTIONARY ADAPTATION; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; POPULATION DYNAMICS; SPATIAL ANALYSIS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; COMPUTER SIMULATION; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; STAPHYLOCOCCUS AUREUS;

EID: 84876847093     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003300     Document Type: Article

References (67)

1. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA: the journal of the American Medical Association 304: 321-333.
2. Connolly LE, Edelstein PH, Ramakrishnan L, (2007) Why is long-term therapy required to cure tuberculosis? PLoS medicine 4: e120.
3. Gorbach SL, (1994) Piperacillin/tazobactam in the treatment of polymicrobial infections. Intensive care medicine 20 Suppl 3: S27-34.
4. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, et al. (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394-434.
5. Barberan J, Aguilar L, Gimenez MJ, Carroquino G, Granizo JJ, et al. (2008) Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. International journal of antimicrobial agents 32: 154-157.
6. Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, et al. (2010) Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrobial agents and chemotherapy 54: 1742-1748.
7. den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW, (1997) Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrobial agents and chemotherapy 41: 95-100.
8. Cappelletty DM, Kang SL, Palmer SM, Rybak MJ, (1995) Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrobial agents and chemotherapy 39: 1797-1801.
9. Kang SL, Rybak MJ, McGrath BJ, Kaatz GW, Seo SM, (1994) Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and-resistant Staphylococcus aureus in an in vitro infection model. Antimicrobial agents and chemotherapy 38: 2702-2709.
10. Kang SL, Rybak MJ, (1995) Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots. Antimicrobial agents and chemotherapy 39: 2832-2834.
11. Johnson DE, Thompson B, (1986) Efficacy of Single-Agent Therapy with Azlocillin, Ticarcillin, and Amikacin and Beta-Lactam Amikacin Combinations for Treatment of Pseudomonas-Aeruginosa Bacteremia in Granulocytopenic Rats. American Journal of Medicine 80: 53-58.
12. Johnson DE, Thompson B, Calia FM, (1985) Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats. Antimicrobial agents and chemotherapy 28: 735-739.
13. Michalsen H, Bergan T, (1981) Azlocillin with and without an Aminoglycoside against Respiratory-Tract Infections in Children with Cystic-Fibrosis. Scandinavian Journal of Infectious Diseases pp. 92-97.
14. Mclaughlin FJ, Matthews WJ, Strieder DJ, Sullivan B, Taneja A, et al. (1983) Clinical and Bacteriological Responses to 3 Antibiotic Regimens for Acute Exacerbations of Cystic-Fibrosis- Ticarcillin-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo. Journal of Infectious Diseases 147: 559-567.
15. Anderson ET, Young LS, Hewitt WL, (1978) Antimicrobial Synergism in Therapy of Gram-Negative Rod Bacteremia. Chemotherapy 24: 45-54.
16. Dejongh CA, Joshi JH, Newman KA, Moody MR, Wharton R, et al. (1986) Antibiotic Synergism and Response in Gram-Negative Bacteremia in Granulocytopenic Cancer-Patients. American Journal of Medicine 80: 96-100.
17. Klasters J, Cappel R, Daneau D, (1972) Clinical Significance of in-Vitro Synergism between Antibiotics in Gram-Negative Infections. Antimicrobial agents and chemotherapy 2: 470-5.
18. Klastersky J, Meuniercarpentier F, Prevost JM, Staquet M, (1976) Synergism between Amikacin and Cefazolin against Klebsiella- Invitro Studies and Effect on Bactericidal Activity of Serum. Journal of Infectious Diseases 134: 271-276.
19. Klastersky J, Hensgens C, Meuniercarpentier F, (1976) Comparative Effectiveness of Combinations of Amikacin with Penicillin-G and Amikacin with Carbenicillin in Gram-Negative Septicemia- Double-Blind Clinical-Trial. Journal of Infectious Diseases 134: S433-S440.
20. Lau WK, Young LS, Black RE, Winston DJ, Linne SR, et al. (1977) Comparative Efficacy and Toxicity of Amikacin-Carbenicillin Versus Gentamicin-Carbenicillin in Leukopenic Patients- Randomized Prospective Trail. American Journal of Medicine 62: 959-966.
21. Jawetz E, Gunnison JB, Speck RS, Coleman VR, (1951) Studies on antibiotic synergism and antagonism; the interference of chloramphenicol with the action of penicillin. AMA archives of internal medicine 87: 349-359.
22. Lepper MH, Dowling HF, (1951) Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. AMA archives of internal medicine 88: 489-494.
23. Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N, (2000) Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. The Journal of antimicrobial chemotherapy 46: 973-980.
24. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, et al. (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 44: 159-177.
25. Hall MJ, Middleton RF, Westmacott D, (1983) The fractional inhibitory concentration (FIC) index as a measure of synergy. The Journal of antimicrobial chemotherapy 11: 427-433.
26. Lorian V (1996) Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins. xvi, 1238 p. p.
27. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, et al. (2004) Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrobial agents and chemotherapy 48: 3670-3676.
28. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R, (2008) Accelerated evolution of resistance in multidrug environments. Proceedings of the National Academy of Sciences of the United States of America 105: 13977-13981.
29. Meletiadis J, Stergiopoulou T, O'Shaughnessy EM, Peter J, Walsh TJ, (2007) Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob Agents Chemother 51: 2053-2064.
30. Berenbaum MC, Yu VL, Felegie TP, (1983) Synergy with double and triple antibiotic combinations compared. J Antimicrob Chemother 12: 555-563.
31. Ankomah P, Levin BR, (2012) Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS pathogens 8: e1002487.
32. Lim TP, Ledesma KR, Chang KT, Hou JG, Kwa AL, et al. (2008) Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrobial agents and chemotherapy 52: 2898-2904.
33. Yeh P, Tschumi AI, Kishony R, (2006) Functional classification of drugs by properties of their pairwise interactions. Nature genetics 38: 489-494.
34. Wood K, Nishida S, Sontag ED, Cluzel P, (2012) Mechanism-independent method for predicting response to multidrug combinations in bacteria. Proceedings of the National Academy of Sciences of the United States of America 109: 12254-12259.
35. Lewis K, (2010) Persister cells. Annual review of microbiology 64: 357-372.
36. Bigger JW, (1944) Treatment of staphylococcal infections with penicillin- By intermittent sterilisation. Lancet 2: 497-500.
37. Hofsteenge N, van Nimwegen E, Silander OK, (2013) Quantitative analysis of persister fractions suggests different mechanisms of formation among environmental isolates of E. coli. BMC Microbiol 13: 25.
38. Allison KR, Brynildsen MP, Collins JJ, (2011) Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473: 216-220.
39. Loewe S, Muischnek H, (1926) Combinated effects I Announcement- Implements to the problem. Naunyn-Schmiedebergs Archiv Fur Experimentelle Pathologie Und Pharmakologie 114: 313-326.
40. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R, (2009) Drug interactions and the evolution of antibiotic resistance. Nature reviews Microbiology 7: 460-466.
41. Johnson PJ, Levin BR, (2013) Pharmacodynamics, Population Dynamics, and the Evolution of Persistence in Staphylococcus aureus. PLoS Genet 9: e1003123.
42. Levin BR, Udekwu KI, (2010) Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments. Antimicrobial agents and chemotherapy 54: 3414-3426.
43. Monod J, (1949) The Growth of Bacterial Cultures. Annual Review of Microbiology 3: 371-394.
44. Wiuff C, Zappala RM, Regoes RR, Garner KN, Baquero F, et al. (2005) Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrobial agents and chemotherapy 49: 1483-1494.
45. Drlica K, (2003) The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17.
46. Davies D, (2003) Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2: 114-122.
47. Wagner C, Sauermann R, Joukhadar C, (2006) Principles of antibiotic penetration into abscess fluid. Pharmacology 78: 1-10.
48. Brown MR, Allison DG, Gilbert P, (1988) Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? The Journal of antimicrobial chemotherapy 22: 777-780.
49. CLSI (2005) Performance Standards for Antimicrobial Susceptibility Testing. Fifteenth Informational Supplement Clinical and Laboratory Standards Institute.
50. Jawetz E, Gunnison JB, (1952) Studies on Antibiotic Synergism and Antagonism- a Scheme of Combined Antibiotic Action. Antibiotics and Chemotherapy 2: 243-248.
51. Pankey GA, Sabath LD, (2004) Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 38: 864-870.
52. Mulcahy LR, Burns JL, Lory S, Lewis K, (2010) Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. Journal of bacteriology 192: 6191-6199.
53. Lafleur MD, Qi Q, Lewis K, (2010) Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrobial agents and chemotherapy 54: 39-44.
54. Chao MC, Rubin EJ, (2010) Letting Sleeping dos Lie: Does Dormancy Play a Role in Tuberculosis? Annual Review of Microbiology, Vol 64, 2010 64: 293-311.
55. Costerton JW, Stewart PS, Greenberg EP, (1999) Bacterial biofilms: A common cause of persistent infections. Science 284: 1318-1322.
56. Chait R, Craney A, Kishony R, (2007) Antibiotic interactions that select against resistance. Nature 446: 668-671.
57. Margolis E, Levin BR, (2008) Evolution of Bacterial-Host Interactions: Virulence and the Immune Overresponse. Evolutionary Biology of Bacterial and Fungal Pathogens pp. 3-12.
58. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ, (2007) A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130: 797-810.
59. Wu Y, Vulic M, Keren I, Lewis K, (2012) Role of oxidative stress in persister tolerance. Antimicrob Agents Chemother 56: 4922-4926.
60. Vega NM, Allison KR, Khalil AS, Collins JJ, (2012) Signaling-mediated bacterial persister formation. Nat Chem Biol 8: 431-433.
61. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, et al. (2011) Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 7: e1002359.
62. Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P, (1999) In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 43: 287-291.
63. Martinez JL, Baquero F, (2002) Interactions among strategies associated with bacterial infection: Pathogenicity, epidemicity, and antibiotic resistance. Clinical Microbiology Reviews 15: 647-679.
64. Martinez-Suarez JV, Martinez JL, Lopez de Goicoechea MJ, Perez-Diaz JC, Baquero F, et al. (1987) Acquisition of antibiotic resistance plasmids in vivo by extraintestinal Salmonella spp. J Antimicrob Chemother 20: 452-453.
65. Bloch CA, Thorne GM, Ausubel FM, (1989) General method for site-directed mutagenesis in Escherichia coli O18ac:K1:H7: deletion of the inducible superoxide dismutase gene, sodA, does not diminish bacteremia in neonatal rats. Infection and immunity 57: 2141-2148.
66. Bull JJ, Levin BR, DeRouin T, Walker N, Bloch CA, (2002) Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC microbiology 2: 35.
67. Dorr T, Vulic M, Lewis K, (2010) Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS biology 8: e1000317.